These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 29589538)

  • 1. Antimicrobial peptides for the treatment of pulmonary tuberculosis, allies or foes?
    Rivas-Santiago B; Torres-Juarez F
    Curr Pharm Des; 2018; 24(10):1138-1147. PubMed ID: 29589538
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interaction between antimicrobial peptides and mycobacteria.
    Gutsmann T
    Biochim Biophys Acta; 2016 May; 1858(5):1034-43. PubMed ID: 26851776
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activity of LL-37, CRAMP and antimicrobial peptide-derived compounds E2, E6 and CP26 against Mycobacterium tuberculosis.
    Rivas-Santiago B; Rivas Santiago CE; Castañeda-Delgado JE; León-Contreras JC; Hancock RE; Hernandez-Pando R
    Int J Antimicrob Agents; 2013 Feb; 41(2):143-8. PubMed ID: 23141114
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potent cationic antimicrobial peptides against Mycobacterium tuberculosis in vitro.
    Silva S; Santos-Silva A; da Costa JMC; Vale N
    J Glob Antimicrob Resist; 2019 Dec; 19():132-135. PubMed ID: 31154008
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ability of innate defence regulator peptides IDR-1002, IDR-HH2 and IDR-1018 to protect against Mycobacterium tuberculosis infections in animal models.
    Rivas-Santiago B; Castañeda-Delgado JE; Rivas Santiago CE; Waldbrook M; González-Curiel I; León-Contreras JC; Enciso-Moreno JA; del Villar V; Mendez-Ramos J; Hancock RE; Hernandez-Pando R
    PLoS One; 2013; 8(3):e59119. PubMed ID: 23555622
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A review on anti-tuberculosis peptides: Impact of peptide structure on anti-tuberculosis activity.
    Yathursan S; Wiles S; Read H; Sarojini V
    J Pept Sci; 2019 Nov; 25(11):e3213. PubMed ID: 31515916
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro activity of 12 antimicrobial peptides against Mycobacterium tuberculosis and Mycobacterium avium clinical isolates.
    Portell-Buj E; Vergara A; Alejo I; López-Gavín A; Monté MR; San Nicolás L; González-Martín J; Tudó G
    J Med Microbiol; 2019 Feb; 68(2):211-215. PubMed ID: 30570475
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antimicrobial peptides as an alternative to anti-tuberculosis drugs.
    AlMatar M; Makky EA; Yakıcı G; Var I; Kayar B; Köksal F
    Pharmacol Res; 2018 Feb; 128():288-305. PubMed ID: 29079429
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Delivery of LLKKK18 loaded into self-assembling hyaluronic acid nanogel for tuberculosis treatment.
    Silva JP; Gonçalves C; Costa C; Sousa J; Silva-Gomes R; Castro AG; Pedrosa J; Appelberg R; Gama FM
    J Control Release; 2016 Aug; 235():112-124. PubMed ID: 27261333
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Natural antimicrobial peptides against Mycobacterium tuberculosis.
    Abedinzadeh M; Gaeini M; Sardari S
    J Antimicrob Chemother; 2015 May; 70(5):1285-9. PubMed ID: 25681127
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tuberculosis and its Treatment: An Overview.
    Bansal R; Sharma D; Singh R
    Mini Rev Med Chem; 2018; 18(1):58-71. PubMed ID: 27553018
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antimicrobial peptides as novel anti-tuberculosis therapeutics.
    Silva JP; Appelberg R; Gama FM
    Biotechnol Adv; 2016; 34(5):924-940. PubMed ID: 27235189
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro activity of PR-39, a proline-arginine-rich peptide, against susceptible and multi-drug-resistant Mycobacterium tuberculosis.
    Linde CM; Hoffner SE; Refai E; Andersson M
    J Antimicrob Chemother; 2001 May; 47(5):575-80. PubMed ID: 11328767
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antimicrobial peptides and proteins in mycobacterial therapy: current status and future prospects.
    Padhi A; Sengupta M; Sengupta S; Roehm KH; Sonawane A
    Tuberculosis (Edinb); 2014 Jul; 94(4):363-73. PubMed ID: 24813349
    [TBL] [Abstract][Full Text] [Related]  

  • 15. B1CTcu5: A frog-derived brevinin-1 peptide with anti-tuberculosis activity.
    Abraham P; Jose L; Maliekal TT; Kumar RA; Kumar KS
    Peptides; 2020 Oct; 132():170373. PubMed ID: 32679168
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antimicrobial Peptides: A Promising Strategy for Anti-tuberculosis Therapeutics.
    Ning Y; Wang L; Wang M; Meng X; Qiao J
    Protein Pept Lett; 2023; 30(4):280-294. PubMed ID: 36924097
    [TBL] [Abstract][Full Text] [Related]  

  • 17. lysX gene is differentially expressed among Mycobacterium tuberculosis strains with different levels of virulence.
    Montoya-Rosales A; Provvedi R; Torres-Juarez F; Enciso-Moreno JA; Hernandez-Pando R; Manganelli R; Rivas-Santiago B
    Tuberculosis (Edinb); 2017 Sep; 106():106-117. PubMed ID: 28802397
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cationic Antimicrobial Peptides for Tuberculosis: A Mini-Review.
    Silva S; Vale N
    Curr Protein Pept Sci; 2019; 20(9):885-892. PubMed ID: 31241433
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Autophagy as a target for therapeutic uses of multifunctional peptides.
    Muciño G; Castro-Obregón S; Hernandez-Pando R; Del Rio G
    IUBMB Life; 2016 Apr; 68(4):259-67. PubMed ID: 26968336
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel derivative of the fungal antimicrobial peptide plectasin is active against Mycobacterium tuberculosis.
    Tenland E; Krishnan N; Rönnholm A; Kalsum S; Puthia M; Mörgelin M; Davoudi M; Otrocka M; Alaridah N; Glegola-Madejska I; Sturegård E; Schmidtchen A; Lerm M; Robertson BD; Godaly G
    Tuberculosis (Edinb); 2018 Dec; 113():231-238. PubMed ID: 30514507
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.